Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025. The meeting is taking place November 5 – 9 at the Gaylord National Convention Center in National … Continued
CHICAGO, September 11, 2025 – Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its updated Tempus Pixel, an AI-powered cardiac imaging platform. This update allows the generation of T1 and … Continued
Background – Inputs into cancer prognostic models are primarily structured data such as demographic and clinicopathological features, and lack richer and temporal context often found in unstructured clinical notes. We hypothesize that creating a temporal clinical patient note from structured data that preserves longitudinal and clinical contextual information, and coupling it with a large language … Continued
Background: The Centers for Medicare & Medicaid Services Bundled Payments For Care Improvement Advanced (BPCI-A) is a payment model promoting delivery of high-value care. We studied predictors of cost of care (CoC) in inpatients enrolled in the cardiac care bundle comprising heart failure (HF), myocardial infarction (MI), and arrhythmias (Ar) as primary diagnosis on admission. … Continued
Abstract Identifying disease phenotypes from electronic health records (EHRs) is critical for numerous secondary uses. Manually encoding physician knowledge into rules is particularly challenging for rare diseases due to inadequate EHR coding, necessitating review of clinical notes. Large language models (LLMs) offer promise in text understanding but may not efficiently handle real-world clinical documentation. We propose a … Continued
Cardiac computed tomography may be useful to assess anatomical characteristics (size, location, path) but is exposed to beam hardening artifacts and to cardiac movements [2]. Conventional cardiac magnetic resonance (CMR) seems to be relevant for functional evaluation of PVL after transcatheter aortic valve replacement, but is highly sensitive to metallic artefacts [3]. The question of … Continued